Skip to main content

Table 2 Clinical and laboratory adverse events of antifungal prophylaxis

From: Caspofungin as antifungal prophylaxis in pediatric patients undergoing allogeneic hematopoietic stem cell transplantation: a retrospective analysis

Variable L-AmB (n = 60) CAS (n = 60) Difference (95% CI)  
  No. of patients (%) Percentage points p-Value
Drug-related adverse events     
 Clinical (Total) 5 (8.33) 2 (3.33) 5.0 (−3.4 to 13.4) 0.243
 Fever 1 (1.67) 1 (1.67) 0.0 (−4.6 to 4.6) 1.0
 Nausea 1 (1.67) 0 1.7 (−1.6 to 4.9) 0.315
 Headache 2 (3.33) 1 (1.67) 1.7 (−3.9 to 7.3) 0.559
 Bone pain 1 (1.67) 0 1.7 (−1.6 to 4.9) 0.315
Increase in alanine aminotransferase     
 ≥ 1.5 × normal value 39 U/L 13 (21.67) 14 (23.33) −1.7 (−16.6 to 13.3) 0.827
 ≥ 2.5 × normal value 39 U/L 3 (5.0) 8 (13.33) −8.3 (−18.7 to 2.0) 0.144
Increase in aspartate aminotransferase     
 ≥ 1.5 × normal value 39 U/L 15 (25.0) 19 (31.67) −6.7 (−22.7 to 9.4) 0.416
 ≥ 2.5 × normal value 39 U/L 6 (10.0) 2 (3.33) 6.7 (−2.2 to 15.5) 0.140
Increase in alkaline phosphatase     
 ≥ 1.5 × normal value 320 U/L 0 0 0 1.0
 ≥ 2.5 × normal value 320 U/L 0 0 0 1.0
Increase in total bilirubin     
 ≥ 1.5 × normal value 1.1 mg/dl 3 (5.0) 0 5.0 (−0.6 to 10.6) 0.079
 ≥ 2.5 × normal value 1.1 mg/dl 0 0 0 1.0
Increase in direct bilirubin     
 ≥ 1.5 × normal value 0.3 mg/dl 9 (15.0) 5 (8.33) 6.7 (−4.8 to 18.2) 0.255
 ≥ 2.5 × normal value 0.3 mg/dl 3 (5.0) 2 (3.33) 1.7 (−5.5 to 8.8) 0.648
Increase in creatinine     
 ≥ 1.5 × normal value 0.7 mg/dl 0 0 0 1.0
 ≥ 2.5 × normal value 0.7 mg/dl 0 0 0 1.0
Increase in urea     
 ≥ 1.5 × normal value 46 mg/dl 3 (5.0) 2 (3.33) 1.7 (−5.5 to 8.8) 0.648
 ≥ 2.5 × normal value 46 mg/dl 0 0 0 1.0
Decrease potassium     
 ≤ 3.4 mmol/L 46 (76.67) 34 (56.67) −20.0 (−3.1 to −36.9) 0.02
 ≤ 2.4 mmol/L 2 (3.33) 0 −3.3 (1.2 to −7.9) 0.154
  1. Abbreviation: CAS, caspofungin; L-AmB, liposomal amphotericin B